Expressed in euros, drug sales increased 6.2% in 2014.
In 2013, Romania’s pharmaceutical market stood at RON11.75 billion.
By distribution channels, retail sales (pharmacies) increased 6.7%, to RON10.84 billion, while the hospital segment rose 8.1%, to RON1.44 billion, Expressed in euros, retail sales rose 6%, to EUR2.44 billion, and sales to hospitals grew 7.4%, to EUR324.2 million.
Sales of prescription drugs rose 5.2%, to RON8.82 billion (+4.5% in euros, to EUR1.98 billion), while over the counter (OTC) medicines rose 13.7%, to RON2 billion(+13.1% in euros, to EUR455.6 million).
In the fourth quarter of 2014, drug sales amounted to RON3.34 billion (EUR753.3 million), up 11.8% compared to the last quarter of 2013. Prescription drugs sold in pharmacies reached RON2.35 billion, up 9.6%, while OTC sales rose 19.5%, to RON590 million. Sales to hospitals grew 13.8% in the fourth quarter, to RON400.
Cegedim revised its growth forecast for the Romanian pharmaceutical market in 2015 from +1.8% to +3.5%, but warns about systemic risk.
The order of Romania’s top 20 pharmaceutical companies has changed compared to 2013, as Sanofi reclaimed the leading position, with sales of RON852 million and a 6.9% market share, overtaking Roche, which had sales of RON804.9 million and a 6.6%% market share. Novartis (including Sandoz) remained at number three, with sales of RON713.5 million and a 5.8% market share.
The top ten in completed by Servier (RON697.9 million), Pfizer (RON627.7 million), Ranbaxy-Terapia (RON522.1 million), GlaxoSmithKline (RON492.8 million), AstraZeneca (RON489.4 million), Merck & Co (RON412.5 million) and Krka (RON364.2 million).
Numbers 11 to 20 are held by Johnson&Johnson, Abbvie, Menarini, Bristol Myers Squibb, Teva, Antibiotice, Bayer, Alvogen, Abbott and Gedeon Richter, which have market shares of 2.5% to 1.5%. Local manufacturer Antibiotice Iasi dropped five spots from its position at number 11 in 2013.